2-D08 |
| Catalog No.GC10408 |
2-D08 es un inhibidor mecÁnicamente Único, permeable a las células, de la SUMOilaciÓn de proteÍnas. 2-D08 también inhibe Axl con un IC50 de 0,49 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 144707-18-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
2-D08 is a synthetic flavonoid and cell-permeable small ubiquitin-like modifier (SUMO) inhibitor, which also inhibits the Axl target with an IC50 of 0.49nM[1]. Protein SUMOylation is a dynamic post-translational modification involved in various biological processes in cellular homeostasis and development. 2-D08 inhibits SUMOylation by preventing the transfer of SUMO from the UBC9-SUMO thioester to substrates[2]. 2-D08 is commonly used to investigate the role of SUMOylation in various biological pathways and diseases, such as acute myeloid leukemia and demyelinating disorders[3,4].
In vitro, incubation of C2C12 myoblasts with 2-D08 (50, 100μM) for 24h induced significant morphological changes and markedly inhibited cell viability, with the highest dose of 100µM reducing cell viability by up to 20%[5]. Treatment of human uterine leiomyosarcoma (Ut-LMS) SK-LMS-1 and SK-UT-1B cell lines with 2-D08 (10-100μM) for 7 days resulted in a dose-dependent decrease in cell survival fraction and inhibited the colony-forming ability of Ut-LMS cells[6]. Incubation of primary cultured oligodendrocyte precursor cells (OPCs) with 2-D08 (50μM) for 72h significantly increased the phosphorylation level of FYN tyrosine kinase and enhanced the expression of Kir4.1 and MBP proteins[4].
In vivo, administration of 2-D08 (1mg/kg; i.p.) daily, starting 48h after MOG35-55 immunization, significantly alleviated disease severity and promoted weight gain during the acute phase in experimental autoimmune encephalomyelitis (EAE) mice at 20 days post-immunization. 2-D08 (1mg/kg; i.v.) administered daily for 30 days, starting after symptom onset in EAE marmosets, promoted spinal cord myelin repair and improved motor coordination[4]. 2-D08 (10mg/kg; every three days) administered via intratumoral injection to C57BL/6J mice bearing RM-1 tumors for 2 weeks significantly suppressed tumor growth, reduced tumor mass, and increased tumor cell apoptosis[7].
References:
[1] FUJINO N, KUBO H, MACIEWICZ R A. Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype[J]. Laboratory Investigation, 2017, 97(9): 1047-1062.
[2] KIM Y S, KEYSER S G L, SCHNEEKLOTH J S J. Synthesis of 2’, 3’, 4’-trihydroxyflavone (2-D08), an inhibitor of protein sumoylation[J]. Bioorganic & Medicinal Chemistry Letters, 2014, 24(4): 1094-1097.
[3] ZHOU P, CHEN X, LI M, et al. 2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2[J]. Biochemical and Biophysical Research Communications, 2019, 513(4): 1063-1069.
[4] LIU M, JIN S, FU X, et al. Activation of Kir4.1 Channels by 2-D08 Promotes Myelin Repair in Multiple Sclerosis[J]. Advanced Science, 2025: e02032.
[5] LIU H, LEE S M, JOUNG H. 2-D08 treatment regulates C2C12 myoblast proliferation and differentiation via the Erk1/2 and proteasome signaling pathways[J]. Journal of Muscle Research and Cell Motility, 2021, 42(2): 193-202.
[6] JOUNG H, LIU H. 2-D08 mediates notable anticancer effects through multiple cellular pathways in uterine leiomyosarcoma cells[J]. Oncology Reports, 2024, 52(1): 97.
[7] XIAO J, SUN F, WANG Y N, et al. UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer[J]. Journal of Clinical Investigation, 2023, 133(4): e158352.
| Cell experiment [1]: | |
Cell lines | C2C12 (Mouse myoblasts cells) |
Preparation Method | C2C12 cells were plated in 96-well plates (5 × 103 cells/well) overnight under conducive growth conditions and treated with the indicated concentration of 2-D08 (0, 10, 20, 50, and 100μM) for 24h. To measure cell viability, the MTT assay was used to measure the cell proliferation rate. |
Reaction Conditions | 0, 10, 20, 50, and 100μM; 24h |
Applications | Treatment of C2C12 cells with 2-D08 (50, 100μM) for 24h induced distinct morphological changes and significantly inhibited cell viability, with the maximum reduction of 20% observed at the highest dose of 100µM. |
| Animal experiment [2]: | |
Animal models | Adult male C57BL/6J mice model of EAE |
Preparation Method | EAE mice were administered 1mg/kg of 2-D08 via daily intraperitoneal (i.p.) injection, starting 48h after immunization (prophylactic treatment). |
Dosage form | 1mg/kg; once daily; i.p. |
Applications | 2-D08 significantly alleviated disease severity and promoted weight gain during the acute phase of EAE in mice at 20 days post-immunization. |
References: | |
| Cas No. | 144707-18-6 | SDF | |
| Chemical Name | 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one | ||
| Canonical SMILES | O=C1C2=CC=CC=C2OC(C3=CC=C(O)C(O)=C3O)=C1 | ||
| Formula | C15H10O5 | M.Wt | 270.2 |
| Solubility | ≤1mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.701 mL | 18.5048 mL | 37.0096 mL |
| 5 mM | 740.2 μL | 3.701 mL | 7.4019 mL |
| 10 mM | 370.1 μL | 1.8505 mL | 3.701 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *